{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/eli-lilly-lly/",
 "dataUrl": "https://clearank.com/stock/eli-lilly-lly/data.json",
 "title": "Eli Lilly (LLY) Stock Forecast & Price Target (2026)",
 "description": "Eli Lilly and Company (LLY) stock: Healthcare, Drug Manufacturers - General. $1.0T market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Eli Lilly and Company (LLY)",
 "published": "2026-05-28T09:15:15+00:00",
 "modified": "2026-09-15T15:31:51.121+00:00",
 "generated": "2026-09-16T11:56:06.905Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "LLY",
  "name": "Eli Lilly and Company",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General",
  "country": "United States",
  "website": "https://www.lilly.com"
 },
 "quote": {
  "price": 1146.56,
  "previousClose": 1138.28,
  "change": 8.28,
  "changePercent": 0.73,
  "open": 1154.815,
  "high": 1160.6,
  "low": 1140.93,
  "volume": 27921,
  "averageVolume": 2017042,
  "marketCap": 1014613946688,
  "fiftyTwoWeekHigh": 1292.65002,
  "fiftyTwoWeekLow": 712.049988,
  "marketOpen": false,
  "asOf": "2026-09-15T15:31:51.000Z"
 },
 "statistics": {
  "pe": 38.1717,
  "eps": 29.82,
  "dividendYield": 0.00603760415303407,
  "beta": 0.502,
  "priceToSales": 12.741337,
  "priceToBook": 29.953161,
  "revenueTtm": 79666003968,
  "grossMargin": 0.8577522416644903,
  "returnOnEquity": 1.02286
 },
 "technicals": {
  "rsi": 22.1,
  "macd": -16.95,
  "sma50": 1182.07,
  "sma200": 1065.37,
  "rsiSignal": "Oversold",
  "trend": "Bullish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 73,
  "consensus": "Buy",
  "fairValue": 1385,
  "analystTarget": 1385,
  "analystCount": 30,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-15T15:31:51.000Z",
  "priceAtAnalysis": 1146.56,
  "volatility": {
   "daily": 2.04,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 1123.63,
  "aggressiveEntry": 1146.56,
  "stopLoss": 1085.76,
  "stopLossPercent": 3.37,
  "targets": [
   1179.81,
   1235.99,
   1292.17
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 900.11,
    "base": 1328.58,
    "upside90th": 1961
   },
   {
    "year": 2028,
    "downside10th": 887.66,
    "base": 1539.49,
    "upside90th": 2669.97
   },
   {
    "year": 2029,
    "downside10th": 908.85,
    "base": 1783.88,
    "upside90th": 3501.39
   },
   {
    "year": 2030,
    "downside10th": 948.8,
    "base": 2067.08,
    "upside90th": 4503.37
   },
   {
    "year": 2031,
    "downside10th": 1002.88,
    "base": 2395.23,
    "upside90th": 5720.64
   },
   {
    "year": 2032,
    "downside10th": 1069.43,
    "base": 2775.47,
    "upside90th": 7203.14
   },
   {
    "year": 2033,
    "downside10th": 1148.04,
    "base": 3216.08,
    "upside90th": 9009.44
   },
   {
    "year": 2034,
    "downside10th": 1238.96,
    "base": 3726.63,
    "upside90th": 11209.26
   },
   {
    "year": 2035,
    "downside10th": 1342.88,
    "base": 4318.24,
    "upside90th": 13886.03
   },
   {
    "year": 2036,
    "downside10th": 1460.78,
    "base": 5003.76,
    "upside90th": 17139.88
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "LLY Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$1,154.82",
    "Day Range": "$1,140.93 to $1,160.60",
    "Prev Close": "$1,138.28",
    "Volume": "27.9K",
    "52-Week Range": "$712.05 to $1,292.65",
    "Market Cap": "$1.01T"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Valuation is broadly in line with sector peers (20% difference), suggesting fair market pricing relative to industry standards."
   ]
  },
  {
   "id": "financials",
   "title": "LLY Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, LLY beat estimates 4 times. The stock rose 3 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "LLY Analysis",
   "text": [
    "Eli Lilly and Company (LLY) is currently trading below its 50-day SMA of $1182.07, indicating a bearish short-term trend, but remains above its 200-day SMA of $1065.37, suggesting the longer-term uptrend is still in place. The stock's RSI is at 22.1, firmly in oversold territory, which historically suggests a potential for a price reversal upwards. The MACD indicator is at -16.95, also pointing to bearish momentum. Key support is identified at the 200-day SMA ($1065.37), while resistance lies near the 50-day SMA ($1182.07) and the current price is approaching the lower bound of its recent trading range. Volume has been significantly below average recently, suggesting a lack of strong conviction from traders during this pullback. The chart structure indicates that while short-term momentum is negative, the underlying long-term trend remains positive, with the oversold RSI presenting a potential buying opportunity for investors anticipating a bounce.",
    "Eli Lilly and Company (LLY) reported EPS of $8.38, exceeding estimates by 27.36%, driving a 1.89% stock price increase and reinforcing positive investor sentiment.",
    "With current year revenue growth projected at 35.00% and next year at 15.00%, LLY significantly outpaces the Healthcare sector's median revenue growth of 8.1%.",
    "LILLY ENDOWMENT, INC. has been systematically reducing its stake in LLY, representing $3.9 billion in sales, as part of a corporate restructuring rather than a bearish signal from management.",
    "The current RSI of 22.1 indicates that LLY is in oversold territory, suggesting a potential for a short-term price rebound.",
    "Eli Lilly and Company (LLY) is expected to continue its strong growth trajectory over the next 6-12 months, driven by its innovative drug pipeline and expanding market share. The company's projected revenue growth of 35.00% for the current year and 15.00% for the next year, significantly outpacing sector averages, underpins a positive base case scenario. Analysts have a median price target of $1385.00, suggesting potential upside from the current price. Key upside catalysts include successful clinical trial results and new drug approvals, which could further accelerate revenue and earnings growth. Conversely, potential risks include increased competition from other pharmaceutical companies, regulatory hurdles, or any unexpected clinical trial failures. The current oversold technical condition, with an RSI of 22.1, presents a favorable entry point for investors anticipating a rebound."
   ],
   "lists": {
    "ProTips": [
     "Eli Lilly and Company (LLY) has an oversold RSI of 22.1, suggesting a potential short-term buying opportunity as the stock may be due for a bounce.",
     "Despite significant insider selling, the narrative indicates it stems from parent company divestitures, not management's lack of conviction, making it a neutral signal.",
     "Consider the premium valuation of LLY; while justified by growth, any slowdown in its pipeline could lead to a significant price correction."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong Earnings Beat in Q2 2026",
     "text": "Eli Lilly and Company (LLY) reported EPS of $8.38, exceeding estimates by 27.36%, driving a 1.89% stock price increase and reinforcing positive investor sentiment.",
     "source": "Company Earnings Report"
    },
    {
     "type": "Bullish",
     "title": "Projected Revenue Growth Exceeds Sector Average",
     "text": "With current year revenue growth projected at 35.00% and next year at 15.00%, LLY significantly outpaces the Healthcare sector's median revenue growth of 8.1%.",
     "source": "Analyst Estimates"
    },
    {
     "type": "Neutral",
     "title": "Parent Company Divestiture",
     "text": "LILLY ENDOWMENT, INC. has been systematically reducing its stake in LLY, representing $3.9 billion in sales, as part of a corporate restructuring rather than a bearish signal from management.",
     "source": "Insider Transaction Data"
    },
    {
     "type": "Bullish",
     "title": "Oversold Technical Conditions",
     "text": "The current RSI of 22.1 indicates that LLY is in oversold territory, suggesting a potential for a short-term price rebound.",
     "source": "Technical Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Eli Lilly and Company (LLY) exhibits a P/E ratio of 38.17, which is higher than the sector median of 31.9, suggesting a premium valuation. However, its Price-to-Sales (P/S) ratio of 12.74 is also above the sector median of 3.7, but this is supported by exceptional revenue growth of 47.7% year-over-year and projected growth of 35.00% for the current year. The company demonstrates outstanding profitability with a net profit margin of 33.53% and a return on equity (ROE) of 102.29%, significantly outperforming the sector's ROE of 6.9%. Its debt-to-equity ratio of 1.62 is slightly above the sector average, but given its strong profitability and growth, it appears manageable. The current valuation, while high, is justified by its leading position in drug manufacturing and its impressive growth trajectory.",
    "Eli Lilly and Company (LLY) has consistently beaten earnings expectations, most recently reporting an EPS of $8.38 for the quarter ending June 2026, which was 27.36% above the estimated $6.58, leading to a 1.89% price increase. This follows a pattern of strong performance, with the company also exceeding estimates in the prior two quarters. The company's revenue growth is strong, with current quarter estimates showing a 26.00% year-over-year increase, indicating sustained demand for its products.",
    "Eli Lilly and Company (LLY) faces valuation risk, with its P/E ratio of 38.17 significantly higher than the sector median of 31.9, indicating that the stock may be overvalued relative to its peers. Despite strong insider selling, the narrative indicates this is primarily driven by parent company divestitures, not management's lack of confidence. However, any unexpected slowdown in its drug pipeline or increased competition could pressure its premium valuation."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "1.01T"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "38.17"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "29.82"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.58%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "1,292.65"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "712.05"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Oversold SMA Cross Bullish Price vs SMA Bearish MACD Bearish Golden Cross in effect with the 50-day SMA ($1,182.07) above the 200-day SMA ($1,065.37), price is trading below the 50-day SMA, RSI at 22.1 suggests oversold conditions; potential bounce setup."
   ],
   "facts": {
    "RSI": "Oversold",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "22.10"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-16.95"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "1,182.07"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "1,065.37"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.27",
    "Correlation with Nasdaq 100 (QQQ)": "+0.18",
    "Correlation with Bitcoin (BTC)": "-0.15",
    "Correlation with Gold (XAU)": "+0.12"
   }
  },
  {
   "id": "trade-plans",
   "title": "LLY Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (22.1) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$1,179.81",
    "TARGET 2": "$1,235.99",
    "TARGET 3": "$1,292.17",
    "STOP LOSS": "$1,085.76"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+2.89%",
    "Average Feb return": "+1.49%",
    "Average Mar return": "-0.02%",
    "Average Apr return": "+3.19%",
    "Average May return": "+3.72%",
    "Average Jun return": "+5.75%",
    "Average Jul return": "-1.12%",
    "Average Aug return": "+4.43%",
    "Average Sep return": "-0.09%",
    "Average Oct return": "+0.48%",
    "Average Nov return": "+4.74%",
    "Average Dec return": "+4.43%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "2.04%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in LLY in September 2016 would be worth about $144,415 today, compared with about $35,344 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in LLY today could grow to about $43,642 by 2036 in the base case, with a bull case near $149,490 and a bear case around $12,741. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "LLY Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $2,067 for LLY by 2030 in the base case, from $1,147 today (1.8x over 4 years). The downside path ends near $949. These are outcomes of a Monte Carlo simulation run on LLY's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using LLY's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "LLY simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$900",
        "$1,329",
        "$1,961"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$888",
        "$1,539",
        "$2,670"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$909",
        "$1,784",
        "$3,501"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$949",
        "$2,067",
        "$4,503"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$1,003",
        "$2,395",
        "$5,721"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$1,069",
        "$2,775",
        "$7,203"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$1,148",
        "$3,216",
        "$9,009"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$1,239",
        "$3,727",
        "$11,209"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$1,343",
        "$4,318",
        "$13,886"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$1,461",
        "$5,004",
        "$17,140"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "IONS Ionis Pharmaceuticals, Inc. NASDAQ $47.25 -8.15%",
     "url": "https://clearank.com/stock/ions-stock-analysis/"
    },
    {
     "text": "MOH Molina Healthcare Inc. NYSE $206.99 -3.31%",
     "url": "https://clearank.com/stock/moh-stock-analysis/"
    },
    {
     "text": "HCA HCA Healthcare, Inc. NYSE $425.76 +0.06%",
     "url": "https://clearank.com/stock/hca-healthcare-hca/"
    },
    {
     "text": "DXCM DexCom Inc. NASDAQ $86.45 +2.09%",
     "url": "https://clearank.com/stock/dxcm-stock-analysis/"
    },
    {
     "text": "MCK McKesson Corporation NYSE $899.56 -1.25%",
     "url": "https://clearank.com/stock/mck-stock-analysis/"
    },
    {
     "text": "TLRY Tilray Brands Inc. NASDAQ $3.99 -3.62%",
     "url": "https://clearank.com/stock/tilray-brands-tlry/"
    },
    {
     "text": "CRSP CRISPR Therapeutics AG NASDAQ $51.83 -2.13%",
     "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
    },
    {
     "text": "BIIB Biogen Inc. NASDAQ $216.17 -0.55%",
     "url": "https://clearank.com/stock/biib-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Compare LLY",
   "links": [
    {
     "text": "LLY vs ABBV Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/lly-vs-abbv/"
    },
    {
     "text": "STZ vs TAP Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/stz-vs-tap/"
    },
    {
     "text": "Silver (XAG) vs Bitcoin (BTC): Scarcity & Price Analysis Head-to-head analysis →",
     "url": "https://clearank.com/compare/silver-vs-bitcoin/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "LLY Insider Trading Analysis",
   "facts": {
    "Bought": "$4.5M",
    "Sold": "$3.9B",
    "Insiders": "25",
    "Avg Transaction": "$71.9M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in LLY",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Jan 7, 2026",
       "cells": [
        "LILLY ENDOWMENT, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "292.1K",
        "$322.4M"
       ]
      },
      {
       "label": "Nov 12, 2025",
       "cells": [
        "LILLY ENDOWMENT, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "305.0K",
        "$308.4M"
       ]
      },
      {
       "label": "Nov 11, 2025",
       "cells": [
        "LILLY ENDOWMENT, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "283.1K",
        "$279.3M"
       ]
      },
      {
       "label": "Nov 3, 2025",
       "cells": [
        "LILLY ENDOWMENT, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "300.0K",
        "$266.6M"
       ]
      },
      {
       "label": "Oct 31, 2025",
       "cells": [
        "LILLY ENDOWMENT, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "301.3K",
        "$260.2M"
       ]
      },
      {
       "label": "Jul 24, 2025",
       "cells": [
        "LILLY ENDOWMENT, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "280.0K",
        "$225.4M"
       ]
      },
      {
       "label": "Mar 3, 2025",
       "cells": [
        "LILLY ENDOWMENT, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "220.0K",
        "$204.3M"
       ]
      },
      {
       "label": "Feb 25, 2025",
       "cells": [
        "LILLY ENDOWMENT, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "225.0K",
        "$203.2M"
       ]
      },
      {
       "label": "Jul 10, 2024",
       "cells": [
        "LILLY ENDOWMENT, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "210.0K",
        "$197.4M"
       ]
      },
      {
       "label": "Feb 6, 2025",
       "cells": [
        "LILLY ENDOWMENT, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "210.0K",
        "$183.6M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Eli+Lilly+and+Company&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Eli Lilly and Company's stock price forecast for 2030?",
   "answer": "Eli Lilly and Company's (LLY) stock price is projected to reach a base case of $2067.08 by 2030, according to Monte Carlo simulations. The downside scenario suggests a price of $948.80, while the upside scenario projects $4503.37. These are statistical outcomes, not guarantees."
  },
  {
   "question": "Is Eli Lilly and Company stock a buy right now?",
   "answer": "Eli Lilly and Company (LLY) is rated a Buy by Wall Street analysts, with a median price target of $1385.00, suggesting a 20.8% upside from the current price of $1146.56. The stock's RSI is oversold at 22.1, indicating a potential buying opportunity."
  },
  {
   "question": "What is Eli Lilly and Company's current valuation compared to its sector?",
   "answer": "Eli Lilly and Company (LLY) trades at a P/E ratio of 38.17 and a P/S ratio of 12.74, both higher than the Healthcare sector medians of 31.9 and 3.7, respectively. This premium valuation is supported by its exceptional revenue growth and profitability."
  },
  {
   "question": "How has Eli Lilly and Company performed in recent earnings reports?",
   "answer": "Eli Lilly and Company (LLY) has consistently beaten earnings estimates, most recently reporting an EPS of $8.38 for the quarter ending June 2026, a 27.36% surprise. This strong performance has contributed to positive price reactions in recent quarters."
  },
  {
   "question": "What are the main risks facing Eli Lilly and Company?",
   "answer": "The primary risks for Eli Lilly and Company (LLY) include its high valuation multiples (P/E of 38.17) and potential competitive pressures in the drug manufacturing sector. Any setbacks in its drug development pipeline could also impact its growth trajectory."
  },
  {
   "question": "What is the insider sentiment for Eli Lilly and Company?",
   "answer": "Insider sentiment for Eli Lilly and Company (LLY) is characterized as a parent company divestiture, with $3.9 billion in sales primarily from LILLY ENDOWMENT, INC. This indicates corporate restructuring rather than a lack of confidence from management, with officer and director selling totaling a more modest $23 million."
  },
  {
   "question": "What is the long-term growth outlook for Eli Lilly and Company?",
   "answer": "Eli Lilly and Company (LLY) has a strong long-term growth outlook, with projected revenue growth of 15.00% for next year and an average annual growth rate of 31.51% projected over the next five years. This is driven by its strong drug pipeline and market leadership."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "IONS",
    "name": "Ionis Pharmaceuticals, Inc. NASDAQ",
    "price": "$47.25",
    "change": "-8.15%",
    "url": "https://clearank.com/stock/ions-stock-analysis/"
   },
   {
    "ticker": "MOH",
    "name": "Molina Healthcare Inc. NYSE",
    "price": "$206.99",
    "change": "-3.31%",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "HCA",
    "name": "HCA Healthcare, Inc. NYSE",
    "price": "$425.76",
    "change": "+0.06%",
    "url": "https://clearank.com/stock/hca-healthcare-hca/"
   },
   {
    "ticker": "DXCM",
    "name": "DexCom Inc. NASDAQ",
    "price": "$86.45",
    "change": "+2.09%",
    "url": "https://clearank.com/stock/dxcm-stock-analysis/"
   },
   {
    "ticker": "MCK",
    "name": "McKesson Corporation NYSE",
    "price": "$899.56",
    "change": "-1.25%",
    "url": "https://clearank.com/stock/mck-stock-analysis/"
   },
   {
    "ticker": "TLRY",
    "name": "Tilray Brands Inc. NASDAQ",
    "price": "$3.99",
    "change": "-3.62%",
    "url": "https://clearank.com/stock/tilray-brands-tlry/"
   },
   {
    "ticker": "CRSP",
    "name": "CRISPR Therapeutics AG NASDAQ",
    "price": "$51.83",
    "change": "-2.13%",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   },
   {
    "ticker": "BIIB",
    "name": "Biogen Inc. NASDAQ",
    "price": "$216.17",
    "change": "-0.55%",
    "url": "https://clearank.com/stock/biib-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "LLY vs ABBV Comparison",
    "name": "",
    "url": "https://clearank.com/compare/lly-vs-abbv/"
   },
   {
    "ticker": "STZ vs TAP Comparison",
    "name": "",
    "url": "https://clearank.com/compare/stz-vs-tap/"
   },
   {
    "ticker": "Silver (XAG) vs Bitcoin (BTC): Scarcity & Price Analysis",
    "name": "",
    "url": "https://clearank.com/compare/silver-vs-bitcoin/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "NTES",
    "text": "NetEase, Inc.",
    "url": "https://clearank.com/stock/ntes-stock-analysis/"
   },
   {
    "ticker": "PCAR",
    "text": "PACCAR Inc.",
    "url": "https://clearank.com/stock/pcar-stock-analysis/"
   },
   {
    "ticker": "O",
    "text": "Realty Income Corp.",
    "url": "https://clearank.com/stock/o-stock-analysis/"
   },
   {
    "ticker": "SPG",
    "text": "Simon Property Group Inc.",
    "url": "https://clearank.com/stock/spg-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "COIN",
    "text": "↓ 10.10%",
    "url": "https://clearank.com/stock/coinbase-coin/"
   },
   {
    "ticker": "AXON",
    "text": "↓ 9.98%",
    "url": "https://clearank.com/stock/axon-enterprise-axon/"
   },
   {
    "ticker": "AERO/USD",
    "text": "↓ 9.65%",
    "url": "https://clearank.com/crypto/aero-usd-crypto-analysis/"
   },
   {
    "ticker": "STX/USD",
    "text": "↓ 9.60%",
    "url": "https://clearank.com/crypto/stx-usd-crypto-analysis/"
   },
   {
    "ticker": "FPS",
    "text": "↑ 9.50%",
    "url": "https://clearank.com/stock/fps-stock-analysis/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "GILD",
    "text": "Gilead Sciences",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "JNJ",
    "text": "Johnson & Johnson",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   },
   {
    "ticker": "MRK",
    "text": "Merck",
    "url": "https://clearank.com/stock/merck-mrk/"
   },
   {
    "ticker": "NVO",
    "text": "Novo Nordisk",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/"
   },
   {
    "ticker": "PFE",
    "text": "Pfizer",
    "url": "https://clearank.com/stock/pfizer-pfe/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/05/LLY-eli-lilly-2026-05.png",
     "url": "https://clearank.com/wp-content/uploads/2026/05/LLY-eli-lilly-2026-05.png",
     "width": "1280",
     "height": "720",
     "caption": "Eli Lilly (LLY) stock price analysis chart for May 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/eli-lilly-lly/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/eli-lilly-lly/",
        "name": "Eli Lilly (LLY) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/eli-lilly-lly/#webpage",
     "url": "https://clearank.com/stock/eli-lilly-lly/",
     "name": "Eli Lilly (LLY) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-05-28T09:15:15+00:00",
     "dateModified": "2026-09-15T15:31:51+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/05/LLY-eli-lilly-2026-05.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/eli-lilly-lly/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/eli-lilly-lly/#richSnippet",
     "headline": "Eli Lilly (LLY) Stock Forecast & Price Target (2026)",
     "name": "Eli Lilly (LLY) Stock Forecast & Price Target (2026)",
     "description": "Eli Lilly and Company (LLY) stock: Healthcare, Drug Manufacturers - General. $1.0T market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-05-28T09:15:15+00:00",
     "dateModified": "2026-09-15T15:31:51+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Eli Lilly and Company",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "LLY"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Eli Lilly and Company is a global medicine company focused on discovering, developing, manufacturing, and marketing human pharmaceutical products. Eli Lilly and Company operates across major therapeutic areas including diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular care, s",
      "tickerSymbol": "LLY",
      "sameAs": "https://www.lilly.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/eli-lilly-lly/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/05/LLY-eli-lilly-2026-05.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/eli-lilly-lly/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Eli Lilly and Company's stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Eli Lilly and Company's (LLY) stock price is projected to reach a base case of $2067.08 by 2030, according to Monte Carlo simulations. The downside scenario suggests a price of $948.80, while the upside scenario projects $4503.37. These are statistical outcomes, not guarantees."
     }
    },
    {
     "@type": "Question",
     "name": "Is Eli Lilly and Company stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Eli Lilly and Company (LLY) is rated a Buy by Wall Street analysts, with a median price target of $1385.00, suggesting a 20.8% upside from the current price of $1146.56. The stock's RSI is oversold at 22.1, indicating a potential buying opportunity."
     }
    },
    {
     "@type": "Question",
     "name": "What is Eli Lilly and Company's current valuation compared to its sector?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Eli Lilly and Company (LLY) trades at a P/E ratio of 38.17 and a P/S ratio of 12.74, both higher than the Healthcare sector medians of 31.9 and 3.7, respectively. This premium valuation is supported by its exceptional revenue growth and profitability."
     }
    },
    {
     "@type": "Question",
     "name": "How has Eli Lilly and Company performed in recent earnings reports?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Eli Lilly and Company (LLY) has consistently beaten earnings estimates, most recently reporting an EPS of $8.38 for the quarter ending June 2026, a 27.36% surprise. This strong performance has contributed to positive price reactions in recent quarters."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main risks facing Eli Lilly and Company?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks for Eli Lilly and Company (LLY) include its high valuation multiples (P/E of 38.17) and potential competitive pressures in the drug manufacturing sector. Any setbacks in its drug development pipeline could also impact its growth trajectory."
     }
    },
    {
     "@type": "Question",
     "name": "What is the insider sentiment for Eli Lilly and Company?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insider sentiment for Eli Lilly and Company (LLY) is characterized as a parent company divestiture, with $3.9 billion in sales primarily from LILLY ENDOWMENT, INC. This indicates corporate restructuring rather than a lack of confidence from management, with officer and director selling totaling a more modest $23 million."
     }
    },
    {
     "@type": "Question",
     "name": "What is the long-term growth outlook for Eli Lilly and Company?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Eli Lilly and Company (LLY) has a strong long-term growth outlook, with projected revenue growth of 15.00% for next year and an average annual growth rate of 31.51% projected over the next five years. This is driven by its strong drug pipeline and market leadership."
     }
    }
   ]
  }
 ]
}